The Effect of Intravenous Ketamine in Suicidal Ideation of Emergency Department Patients
Archives of Academic Emergency Medicine,
Vol. 2 No. 1 (2014),
1 February 2014
,
Page 36-39
https://doi.org/10.22037/aaem.v2i1.20
Abstract
Introduction: Suicidal ideation is an emergent problem in the Emergency Department (ED) that often complicates patient disposition and discharge. It has been shown that ketamine possesses fast acting antidepressant and anti-suicidal effects. This study was conducted to examine the effects of a single intravenous bolus of ketamine on patients with suicidal ideations in ED. Methods: Forty-nine subjects with suicidal ideations with or without an unsuccessful suicide attempt, received 0.2 mg/kg of ketamine. Scale for suicidal ideation (SSI) and Montgomery-Abserg depression-rating scale (MADRS) were evaluated before and 40, 80 and 120 minutes after drug intervention. The results were compared using the paired t-test and patients were followed up 10 days after ED admission for remnant suicide ideation. Results: SSI (df: 3, 46; F=80.7; p<0.001) and MADRS (df: 3, 46; F=87.2; p<0.001) scores significantly dropped after ketamine injection; the SSI score before and after 20, 40, and 80 minutes of ketamine injection were 23.0±6.7, 16.2±5.2, 14.3±4.3, and 13.6±4.0 respectively. The MADRS scores were 38.2±9.3, 25.6±7.1, 22.7±6.3, and 22.1±5.95 at the same time intervals. 25.5% of patients were hospitalized, 63.3% received medications and 12.2% discharged. 6.2% of patients had suicidal ideations ten days after ED disposition.  Conclusion: It seems that Ketamine could not be a good choice for fast reduction of suicidal ideations in ED patients. Further studies are needed to determine the optimal dose of ketamine for different patients.- Ketamine
- suicide
- suicidal ideation
- emergency
How to Cite
References
Deisenhammer EA, Strauss R, Kemmler G, Hinterhuber H, Weiss EM. The duration of the suicidal process: how much time is left for intervention between consideration and accomplishment of a suicide attempt? J Clin Psychiatry. 2009; 70(1):19-24.
Linehan MM, Comtois KA, Murray AM, et al. Two-year randomized controlled trial and follow-up of dialectical behavior therapy vs therapy by experts for suicidal behaviors and borderline personality disorder. Arch Gen Psychiatry. 2006;63(7):757-66.
Brown GK, Ten Have T, Henriques GR, Xie SX, Hollander JE, Beck AT. Cognitive therapy for the prevention of suicide attempts: a randomized controlled trial. JAMA. 2005;294(5): 563-70.
Gausset M, Casadebaig F, Guillaud-Bataille J, Quemada N, Terra J. [Mortality of mentally ill patients. Review of the literature]. L'Encephale. 1991;18(1):93-100.
Hunt IM, Kapur N, Webb R, et al. Suicide in recently disch-arged psychiatric patients: a case-control study. Psychol Med. 2009;39(3):443-9.
Janofsky JS. Reducing inpatient suicide risk: Using human factors analysis to improve observation practices. J Am Acad Psychiatry Law. 2009;37(1):15-24.
Mills PD, DeRosier JM, Ballot BA, Shepherd M, Bagian JP. Inpatient suicide and suicide attempts in Veterans Affairs hospitals. Jt Comm J Qual Patient Saf. 2008;34(8):482-8.
Yeager KR, Saveanu R, Roberts AR, et al. Measured response to identified suicide risk and violence: What you need to know about psychiatric patient safety. Brief Treat Crisis Interv. 2005;5(2):121-8.
Jick H, Kaye JA, Jick SS. Antidepressants and the risk of suici-dal behaviors. JAMA. 2004;292(3):338-43.
Baldessarini RJ, Tondo L, Davis P, Pompili M, Goodwin FK, Hennen J. Decreased risk of suicides and attempts during longâ€term lithium treatment: a metaâ€analytic review. Bipolar disord. 2006;8:625-39.
Meltzer HY, Alphs L, Green AI, et al. Clozapine treatment for suicidality in schizophrenia: international suicide preven-tion trial (InterSePT). Arch Gen Psychiatry. 2003;60(1):82-91.
Reeves H, Batra S, May RS, Zhang R, Dahl DC, Li X. Efficacy of risperidone augmentation to antidepressants in the management of suicidality in major depressive disorder: a randomized, double-blind, placebo-controlled pilot study. J Clin Psychiatry. 2008;69(8):1228-36.
Ernst CL, Goldberg JF. Antisuicide properties of psychotro-pic drugs: a critical review. Harv Rev Psychiatry. 2004;12(1): 14-41.
Zarate CA, Singh JB, Carlson PJ, et al. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry. 2006;63(8):856-64.
Berman RM, Cappiello A, Anand A, et al. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry. 2000;47(4):351-4.
Mathew SJ, Murrough JW, Collins KA, Reich DL, Charney DS. Riluzole for relapse prevention following intravenous ketamine in treatment-resistant depression: a pilot random-ized, placebo-controlled continuation trial. Int J Neuropsycho-pharmacol. 2010;13(01):71-82.
Holi MM, Pelkonen M, Karlsson L, et al. Psychometric properties and clinical utility of the Scale for Suicidal Ideation (SSI) in adolescents. BMC Psychiatry. 2005;5(1):8.
DiazGranados N, Ibrahim L, Brutsche N, et al. Rapid resolu-tion of suicidal ideation after a single infusion of an NMDA antagonist in patients with treatment-resistant major depres-sive disorder. J Clin Psychiatry. 2010;71(12):1605-11.
Price RB, Nock MK, Charney DS, Mathew SJ. Effects of intravenous ketamine on explicit and implicit measures of suicidality in treatment-resistant depression. Biol Psychiatry. 2009;66(5):522-6.
Larkin GL, Beautrais AL. A preliminary naturalistic study of low-dose ketamine for depression and suicide ideation in the emergency department. Int J Neuropsychopharmacol. 2011;14(8):1127-31.
Thangathurai D, Mogos M. Ketamine alleviates fear, depression, and suicidal ideation in terminally ill patients. J Palliat Med. 2011;14(4):389-92.
US Department of Health and Human Services. National strategy for suicide prevention: Goals and objectives for acti-on. 2001 Contract No.: SMA 3517.
Kuehn BM. Soldier suicide rates continue to rise. JAMA. 2009;301(11):1111-3.
- Abstract Viewed: 388 times
- PDF Downloaded: 2977 times
- HTML Downloaded: 45 times
Download Statastics
Make a Submission
SJR
COPE
